Project Grant R15AI183096
Award Date
2/24/25
Completion Date
2/23/28
Dollars Obligated
$440K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an antigen-specific cell therapy for treating myasthenia gravis (MG). The primary grant recipient, George Washington University, will optimize the transduction of regulatory T cells (Tregs) with chimeric antigen receptors (CARs) specific to acetylcholine receptors (AChRs) to suppress the autoimmune...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,199,592 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System Incorporated. The 5-year award, effective June 21, 2024, will support research to identify transcriptional regulators and functional mechanisms of TIM-1+ regulatory B cells in maintaining immune tolerance and limiting autoimmunity in the central...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop engineered mesenchymal stromal cells (MSCs) with enhanced immunosuppressive and trafficking capabilities. The total award of $1,504,225 is being provided to Mayo Clinic to leverage their expertise in viral vectors, CRISPR, preclinical models, and biobanks to engineer CAR-MSCs and evaluate their therapeutic efficacy in treating graft...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,217,020 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Colorado-Denver. The five-year grant, active from May 2024 to March 2029, will fund research to understand the role of the CXCR4 chemokine receptor and integrins in central B cell tolerance and their impact on peripheral tolerance and autoimmune responses. The research aims to generate a deeper...
This $501,011 Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate the use of biodegradable polymeric microparticles comprised of acetalated dextran (Ace-Dex) to induce immune tolerance for the treatment of autoimmune diseases. Key objectives include characterizing the protein corona on the Ace-Dex microparticles that enables...
This $300,000 Project Grant was awarded on April 9, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports Optimeos Life Sciences, Inc., a biotechnology company, in developing an off-the-shelf, in situ chimeric antigen receptor regulatory T cell (CAR-Treg) therapy for treating transplant rejection. The project aims to overcome limitations of current ex vivo CAR-Treg therapies by...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing a novel dendritic cell-based therapy to prevent graft-versus-host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation. The $299,989 grant, awarded on May 7, 2024, aims to determine the in vivo fate of exopolysaccharide-treated dendritic cells, optimize their...
This $461,641 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID, CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of CD4 T cell autoreactivity that occur following checkpoint inhibitor immunotherapy. The primary objectives are to: 1) characterize the phenotype and antigen-specificity of CD4+ T cells involved in the development of autoimmune inflammatory arthritis after checkpoint inhibitor treatment,...
This federal Project Grant award of $299,974.00, issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop and translate effective regulatory T cell (Treg) therapies to suppress anti-drug antibody (ADA) responses to biotherapeutics, with a focus on clotting factor replacement therapy for hemophilia.
The key objectives are to: 1) optimize synthetic receptor design and understand...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $128,250 to the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to develop safer and more specific chimeric antigen receptor (CAR) T cell therapies targeting the PD-1 immune checkpoint protein. The goal is to eliminate HIV-infected CD4 T follicular helper cells within B cell follicles, which serve as a...